Financial Position - As of September 30, 2024, the company had $9.6 million in cash, sufficient to fund operations for the next interim read-out and current commercialization efforts for RenovoCath[1]. - General and administrative expenses decreased to approximately $1.2 million for Q3 2024, down from $1.4 million in the same period last year[11]. - The net loss for Q3 2024 was $2.5 million, compared to a net loss of $1.4 million for Q3 2023[12]. Research and Development - Research and development expenses for Q3 2024 were approximately $1.7 million, remaining flat compared to the same period last year[10]. - RenovoRx signed a new work order with Medical Murray to increase production of RenovoCath devices[4]. Clinical Trials - The ongoing pivotal Phase III TIGeR-PaC clinical trial is expected to complete patient enrollment in the first half of 2025[2]. - The first patient was enrolled at the University of Nebraska Medical Center for the TIGeR-PaC trial, which is anticipated to drive enrollment completion[7]. - The second interim analysis for the TIGeR-PaC study will be triggered by the 52 event, estimated to occur in late 2024 or early 2025[15]. Commercial Strategy - The company expects its RenovoCath commercial strategy to potentially generate revenue in 2025[5]. - RenovoCath received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing 7 years of market exclusivity upon NDA approval by the FDA[18].
RenovoRx(RNXT) - 2024 Q3 - Quarterly Results